Management of Treatment-Experienced HIV-Infected Patients
Summary
- Based on available data, the combination of lopinavir/ritonavir plus either NRTIs or twice-daily raltegravir can be used to successfully treat patients experiencing virologic failure of first-line NNRTI-based therapy
- However, in clinical practice in the developed world it is more common for boosted darunavir or dolutegravir plus NRTIs to be used in this setting
- Results from the DAWNING trial support the efficacy of dolutegravir plus 2 NRTIs after failure of a first-line regimen consisting of an NNRTI plus 2 NRTIs, with the caveat that in this study the second-line regimen was required to include at least 1 active NRTI by resistance testing
Action required
- Login now to access all of your entitled content
or - View additional options to gain access to this content